(6E,8Z,10E,14Z)-(5S,12R)-5,12-Dihydroxy-icosa-6,8,10,14-tetraenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (6E,8Z,10E,14Z)-(5S,12R)-5,12-Dihydroxy-icosa-6,8,10,14-tetraenoic acid
• 英文别名: Delta(6)-trans,Delta(8)-cis-leukotriene B4；(5S,6E,8Z,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid
• 化学式: C₂₀H₃₂O₄
• 分子量: 336.472
• InChiKey: VNYSSYRCGWBHLG-GEWAPNICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(6,7-二甲氧基-4-甲基-3-氧代喹喔啉-2-基)丙酰肼 、 (6E,8Z,10E,14Z)-(5S,12R)-5,12-Dihydroxy-icosa-6,8,10,14-tetraenoic acid 生成 (5S,6E,8Z,10E,12R,14Z)-N'-[3-(6,7-dimethoxy-4-methyl-3-oxoquinoxalin-2-yl)propanoyl]-5,12-dihydroxyicosa-6,8,10,14-tetraenehydrazide
  参考文献：
  名称：

  YAMAGUCHI, MASATOSHI;IWATA, TETSUHARU;INOUE, KOUJI;HARA, SHUUJI;NAKAMURA,+, ANALYST, 115,(1990) N0, C. 1363-1366

  摘要：

  DOI：
• 作为产物：
  描述：

  生成 (6E,8Z,10E,14Z)-(5S,12R)-5,12-Dihydroxy-icosa-6,8,10,14-tetraenoic acid
  参考文献：
  名称：

  Total Synthesis of 6-Trans, 10-cis and (plus or minus) -6-Trans,8-cis Isomers of Leukotriene B

  摘要：

  DOI：

  10.1021/ja00547a600

文献信息

• [EN] THERAPEUTIC AGENTS AND METHODS OF PRODUCING SAME<br/>[FR] AGENTS THÉRAPEUTIQUES ET LEUR PROCÉDÉ DE PRODUCTION
  申请人：GLYCAN BIOSCIENCES LLC

  公开号：WO2018068090A1

  公开（公告）日：2018-04-19

  The present invention relates generally to the field of glycanics and its application to the generation of glycoconjugates for therapeutic use. The present invention also relates to process for the preparation of glycoconjugates.

  本发明总体涉及糖工程领域及其在生成用于治疗用途的糖缀合物中的应用。本发明还涉及制备糖缀合物的方法。
• [EN] ARYL SULFONAMIDES AS BLT1 ANTAGONISTS<br/>[FR] SULFONAMIDES D'ARYLE UTILISÉS EN TANT QU'ANTAGONISTES DE BLT1
  申请人：MERCK SHARP & DOHME

  公开号：WO2017095725A1

  公开（公告）日：2017-06-08

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.

  结构式(I)的新化合物及其药学上可接受的盐是白三烯B4受体1（BLT1）拮抗剂，可能在治疗、预防和抑制由白三烯B4受体1（BLT1）介导的疾病方面有用。本发明的化合物可能在治疗2型糖尿病、胰岛素抵抗、高血糖、血脂异常、脂质紊乱、肥胖、高血压、非酒精性脂肪肝病/非酒精性脂肪性肝炎、代谢综合征、动脉粥样硬化和癌症方面有用。
• Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
  申请人：Pharmacia Corporation

  公开号：US20030220374A1

  公开（公告）日：2003-11-27

  Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of cardiovascular disease or disorder, and for the treatment or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor-&ggr; agonist and a cyclooxygenase-2 selective inhibitor or prodrug thereof. Compositions, pharmaceutical compositions and kits for effecting the particular methods are also described.

  治疗、预防或抑制疼痛、炎症或与炎症相关的疾病，以及治疗或抑制心血管疾病或疾病，以及治疗或抑制需要这种治疗、预防或抑制的患者的癌症的方法包括使用过氧化物酶体增殖物激活受体-γ激动剂和环氧合酶-2选择性抑制剂或其前体来治疗患者。还描述了用于实施特定方法的组合物、药物组合物和工具包。
• Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
  申请人：Pharmacia Corporation

  公开号：US20030157061A1

  公开（公告）日：2003-08-21

  A method for the prevention, treatment, or inhibition of pain, inflammation, or inflammation-related disorder and for the prevention, treatment, or inhibition of a cardiovascular disease or disorder in a subject that is in need of such prevention, treatment or inhibition, involves the administration to the subject of a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNF&agr; antagonist. A method can also involve the treatment, prevention, or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, by administering to the subject a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNF&agr; antagonist which is selected from the group consisting of a compound that affects the synthesis of TNF&agr;, a compound that inhibits the binding of TNF&agr; with a receptor specific for TNF&agr;, and a compound that interferes with intracellular signaling triggered by TNF&agr; binding with a receptor. Compositions, pharmaceutical compositions and kits that can be used with the methods are also described.

  一种用于预防、治疗或抑制疼痛、炎症或与炎症相关的疾病以及预防、治疗或抑制患有心血管疾病或紊乱的受试者的方法，涉及向受试者施用环氧合酶-2选择性抑制剂或其前药以及TNF&agr;拮抗剂。该方法还可以涉及向有需要的受试者施用环氧合酶-2选择性抑制剂或其前药以及从影响TNF&agr;合成的化合物、抑制TNF&agr;与特异于TNF&agr;的受体结合的化合物和干扰由TNF&agr;与受体结合引发的细胞内信号传导的化合物中选择的TNF&agr;拮抗剂，以治疗、预防或抑制癌症。还描述了可与这些方法一起使用的组合物、药物组合物和试剂盒。
• Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
  申请人：Pharmacia Corporation

  公开号：US20030212138A1

  公开（公告）日：2003-11-13

  Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of cardiovascular disease or disorder, and for the treatment or inhibition of cancer, and for the treatment of Alzheimer's disease in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor-&agr; agonist and a cyclooxygenase-2 selective inhibitor or prodrug thereof. Compositions, pharmaceutical compositions and kits for effecting the particular methods are also described.

  用于治疗、预防或抑制疼痛、炎症或与炎症相关的疾病，以及用于治疗或抑制心血管疾病或疾病，以及用于治疗或抑制癌症，以及用于治疗患有阿尔茨海默病的患者的方法包括使用过氧化物酶体增殖物激活受体-α激动剂和环氧合酶-2选择性抑制剂或其前体治疗患者。还描述了用于实施特定方法的组合物、药物组合物和工具包。